Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles

Colloids and Surfaces B: Biointerfaces

Volumn 117, Issue , 2014, Pages 21-28

  Dolatabadi, Jafar Ezzati Nazhad ^a,b   Hamishehkar, Hamed ^c   Eskandani, Morteza ^a,b   Valizadeh, Hadi ^b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alendronate sodium; Compritol; Cytotoxicity; SLN; Solid lipid nanoparticle

Indexed keywords

ALENDRONATE SODIUMS (ALN); COMPRITOL; DRUG ENCAPSULATION EFFICIENCY; ENCAPSULATION EFFICIENCY; SCANNING ELECTRON MICROSCOPY IMAGE; SLN; SOLID LIPID NANOPARTICLE (SLN); SOLID LIPID NANOPARTICLES;

BIOCOMPATIBILITY; DRUG DELIVERY; ENCAPSULATION; HOMOGENIZATION METHOD; NANOPARTICLES; SCANNING ELECTRON MICROSCOPY; SODIUM;

CYTOTOXICITY;

4',6 DIAMIDINO 2 PHENYLINDOLE; ALENDRONIC ACID; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; PHTHALALDEHYDE; POLYSORBATE 20; SOLID LIPID NANOPARTICLE; FLUORESCEIN ISOTHIOCYANATE; INDOLE DERIVATIVE; LIPID; LIPOCORTIN 5; NANOPARTICLE;

ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CELL STRAIN A549; CHEMICAL PROCEDURES; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DERIVATIZATION; DISPERSION; DNA FRAGMENTATION ASSAY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; FLOW CYTOMETRY; HOT HOMOGENIZATION; HUMAN; HUMAN CELL; HYDROPHILICITY; MTT ASSAY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL PARAMETERS; POLYDISPERSITY INDEX; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STAINING; ULTRAFILTRATION; ZETA POTENTIAL; APOPTOSIS; CELL DEATH; CELL PROLIFERATION; DNA FRAGMENTATION; DRUG EFFECTS; METABOLISM; TIME; TOXICITY; TUMOR CELL LINE; ULTRASTRUCTURE;

ALENDRONATE; ANNEXIN A5; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; INDOLES; LIPIDS; NANOPARTICLES; PARTICLE SIZE; STAINING AND LABELING; TIME FACTORS;

EID: 84896765956     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.01.055     Document Type: Article

References (41)

1. Hao J., Wang F., Wang X., Zhang D., Bi Y., Gao Y., Zhao X., Zhang Q. Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. Eur. J. Pharm. Sci. 2012, 47:497.
2. Wang Y., Zhu L., Dong Z., Xie S., Chen X., Lu M., Wang X., Li X., Zhou W. Preparation and stability study of norfloxacin-loaded solid lipid nanoparticle suspensions. Colloids and Surfaces B: Biointerfaces 2012, 98:105.
3. Silva A.C., Kumar A., Wild W., Ferreira D., Santos D., Forbes B. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int. J. Pharm. 2012, 436:798.
4. Lim S.B., Banerjee A., Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release 2012, 163:34.
5. Negi J.S., Chattopadhyay P., Sharma A.K., Ram V. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur. J. Pharm. Sci. 2013, 48:231.
6. Das S., Ng W.K., Tan R.B.H. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?. Eur. J. Pharm. Sci. 2012, 47:139.
7. Bose S., Du Y., Takhistov P., Michniak-Kohn B. Formulation optimization and topical delivery of quercetin from solid lipid based nanosystems. Int. J. Pharm. 2013, 441:56.
8. Bose S., Michniak-Kohn B. Preparation and characterization of lipid based nanosystems for topical delivery of quercetin. Eur. J. Pharm. Sci. 2013, 48:442.
9. Sultana S., Ali R., Talegaonkar S., Ahmad F.J., Mittal G., Bhatnagar A. In vivo lung deposition and sub-acute inhalation toxicity studies of nano-sized alendronate sodium as an antidote for inhaled toxic substances in Sprague Dawley rats. Environ. Toxicol. Pharmacol. 2013, 36:636.
10. Walash M.I., Metwally M.E., Eid M., El-Shaheny R.N. Validated spectrophotometric methods for determination of Alendronate sodium in tablets through nucleophilic aromatic substitution reactions. Chemistry Central Journal 2012, 6:25.
11. Gupta V.K., Jain R., Sharma S., Agarwal S., Dwivedi A. Quantitative determination of alendronate in human urine. Int. J. Electrochem. Sci. 2012, 7:569.
12. Ezzati Nazhad Dolatabadi J., Hamishehkar H., de la Guardia M., Valizadeh H. A fast and simple spectrofluorometric method for the determination of alendronate sodium in pharmaceuticals. BioImpacts 2014, 4. (in press). 10.5681/bi.2014.005.
13. Graham, Malaty Alendronate gastric ulcers. Alimentary Pharmacology & Therapeutics 1999, 13:515.
14. Marshall J.K., Rainsford K.D., James C., Hunt R.H. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Alimentary Pharmacology & Therapeutics 2000, 14:1451.
15. Lanza F. Bisphosphonate mucosal injury-the end of the story?. Digestive Liver Disease 2003, 35:67.
16. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996, 18:75.
17. Cruz L., Fattal E., Tasso L., Freitas G.C., Carregaro A.B., Guterres S.S., Pohlmann A.R., Tsapis N. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J. Control. Release 2011, 152:370.
18. Karie S., Launay-Vacher V., Izzedine H., Deray G. Drug-induced nephrotoxicity: Bibliography from January 2003 to December 2005. Nephrology Therapy 2006, 2:368.
19. Monkkonen J., Koponen H.M., Ylitalo P. Comparison of the distribution of three bisphosphonates in mice. Pharmacology Toxicology 1990, 66:294.
20. Chaturvedi N.P., Solanki H. Pulmonary drug delivery system: review. International Journal of Applied Pharmaceutics 2013, 5:7.
21. Sutton S.C., Engle K., Fix J.A. Intranasal delivery of the bisphosphonate alendronate in the rat and dog. Pharm. Res. 1993, 10:924.
22. Souto E.B., Wissing S.A., Barbosa C.M., Müller R.H. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur. J. Pharm. Biopharm. 2004, 58:83.
23. Mussi S.V., Silva R.C., Oliveira M.C.d., Lucci C.M., Azevedo R.B.d., Ferreira L.A.M. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur. J. Pharm. Sci. 2013, 48:282.
24. Vandghanooni S., Forouharmehr A., Eskandani M., Barzegari A., Kafil V., Kashanian S., Ezzati Nazhad Dolatabadi J. Cytotoxicity and DNA fragmentation properties of butylated hydroxyanisole. DNA Cell Biol. 2013, 32:98.
25. Eskandani M., Hamishehkar H., Ezzati Nazhad Dolatabadi J. Cyto/genotoxicity study of polyoxyethylene (20) sorbitan monolaurate (Tween 20). DNA Cell Biol. 2013, 32:498.
26. Nath M., Vats M., Roy P. Tri- and diorganotin(IV) complexes of biologically important orotic acid: synthesis, spectroscopic studies, in vitro anti-cancer, DNA fragmentation, enzyme assays and in vivo anti-inflammatory activities. Eur. J. Med. Chem. 2012.
27. Gooch J.L., Yee D. Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Lett. 1999, 144:31.
28. Muller R.H., Shegokar R., Keck C.M. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Current Drug Discovery Technologies 2011, 8:207.
29. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews 2001, 47:165.
30. von Knoch F., Jaquiery C., Kowalsky M., Schaeren S., Alabre C., Martin I., Rubash H.E., Shanbhag A.S. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005, 26:6941.
31. Huang W., Liu W., She Z., Wu H., Shi X. Alendronate decorated nano hydroxyapatite in mesoporous silica: Cytotoxicity and osteogenic properties. Appl. Surf. Sci. 2011, 257:9757.
32. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161.
33. Jenning V., Schäfer-Korting M., Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Control. Release 2000, 66:115.
34. Mojahedian M.M., Daneshamouz S., Samani S.M., Zargaran A. A novel method to produce solid lipid nanoparticles using n-butanol as an additional co-surfactant according to the o/w microemulsion quenching technique. Chem. Phys. Lipids 2013, 174:32.
35. Beloqui A., Coco R., Alhouayek M., Solinís M.Á., Rodríguez-Gascón A., Muccioli G.G., Préat V. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int. J. Pharm. 2013, 454:775.
36. Miao J., Du Y.-Z., Yuan H., Zhang X.-g., Hu F.-Q. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids and Surfaces B: Biointerfaces 2013, 110:74.
37. Singh H., Bhandari R., Kaur I.P. Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH. Int. J. Pharm. 2013, 446:106.
38. Xue M., Jiang Z.-z., Wu T., Li J., Zhang L., Zhao Y., Li X.-j., Zhang L.-Y., Yang S.-y. Anti-inflammatory effects and hepatotoxicity of Tripterygium-loaded solid lipid nanoparticles on adjuvant-induced arthritis in rats. Phytomedicine 2012, 19:998.
39. Cohen-Sela E., Rosenzweig O., Gao J., Epstein H., Gati I., Reich R., Danenberg H.D., Golomb G. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J. Control. Release 2006, 113:23.
40. Madan J., Pandey R.S., Jain V., Katare O.P., Chandra R., Katyal A. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine: Nanotechnology, Biology and Medicine 2013, 9:492.
41. Pignatello R., Cenni E., Micieli D., Fotia C., Salerno M., Granchi D., Avnet S., Sarpietro M.G., Castelli F., Baldini N. A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate. Nanomedicine (London) 2009, 4:161.